Sarepta Therapeutic (SRPT) PT Cut to $38 at Needham & Company; 'Buy' Maintained
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cowen Downgrades Sarepta Therapeutic (SRPT) to Market Perform
February 27, 2015 9:15 AM ESTCowen downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Outperform to Market Perform and removed its price target (prior $19.00).
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $13.82 yesterday.
... MoreBaird Maintains Neutral View on Sarepta Therapeutic (SRPT) Post Q4
February 27, 2015 9:07 AM ESTBaird analyst Brian Skorney reiterated a Neutral rating and $16 price target on Sarepta Therapeutic (NASDAQ: SRPT) following Q4 results.
Skorney commented, "No change to outlook following 4Q14. We're remaining on the sidelines here after the 4Q14 update didn't give us enough... More
Sarepta Therapeutics (SRPT) Posts Wider Q4 Loss; NDA Submission for Eteplirsen Planned for Mid-Year 2015
February 26, 2015 7:07 AM ESTSarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($0.94), $0.12 worse than the analyst estimate of ($0.82). Revenue for the quarter came in at $27 thousand versus the consensus estimate of $1.56 million.
Cash and Other Investments of $211 Million at Year End 2014.NDA submission for eteplirsen planned for mid-year 2015 -Plan to discuss new data and NDA submission with FDA in 2nd QuarterLast month we released 168 week data from our Phase IIb study of eteplirsen. We believe the long-term safety of our drug with the continued ambulation and stability of pulmonary... More
